What’s Next for Eli Lilly Alzheimer’s Drug Donanemab? Trial Enrollment Continues
By
Alexandra Marvar
| March 15th, 2021
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…